GPCR

16.3004.79%
DG

Daniel G. Welch

Independent Non-Executive Chairman

Mr. Daniel G. Welch, also known as Dan, is President & Director of Poplar Therapeutics, Inc. He swerves as Chairman since June 2026 at Kinaset Therapeutics. Mr. Welch is Independent Chairman of Prothena Corporation plc from May 14, 2024. Mr. Welch is Independent Director of Prothena Corporation plc from February 2024. He serves as Member of Strategic Advisory Board at Coherus Oncology, Inc. (formerly known as Coherus BioSciences, Inc.) since September 2023. He has been the Independent Chairman at Structure Therapeutics Inc. (formerly known as ShouTi, Inc.). since January 2022 and its Independent Director. Mr. Welch?s global commercial background and strong senior executive experience at a wide range of biotechnology companies, including previously serving as Chairman and Chief Executive Officer of two publicly-traded biotechnology companies, InterMune, Inc. and Triangle Pharmaceuticals, Inc., gives him insight into strategy and planning for a biopharmaceutical company. He joined Structure Therapeutics Inc. (formerly known as ShouTi, Inc.). in January 2022. He was the Chairman of the Board at Nuvation Bio Inc since July 2020 until September 03, 2024. He has been the Non-Executive Chairman of the Board at Ultragenyx Pharmaceutical Inc. since June 18, 2015. Mr. Welch has been Executive Chairman of Board for InCarda Therapeutics, Inc., since March 3, 2019. He was an Executive Partner of Private Equity at Sofinnova Ventures, Inc. from January 2015 to February 2018. Mr. Welch joined Sofinnova to leverage his significant management expertise in support of building innovative life science companies from clinical stage drug development to large-scale commercialization. Mr. Welch has a distinguished track record as a life sciences executive. Mr. Welch served as the Chief Executive Officer and President at InterMune, Inc. from September 25, 2003 to October 2014. He served as the Chairman of InterMune, Inc. from May 13, 2008 to September 29, 2014. He served as Vice President of Worldwide Marketing at Sanofi. From March 2003 to September 2003, Mr. Welch was a Consultant to Warburg Pincus LLC. Prior to InterMune, he served as the Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., from August 2002 to January 2003. Mr. Welch also served as a Director at the firm. Prior to joining Triangle, he served as the President of the Biopharmaceuticals Division at Elan Corporation, plc from October 2000 to July 2002 where he was responsible for U.S. commercial operations, the international subsidiaries, the R&D function and the diagnostics businesses. From September 1987 to August 2000, he held various Executive positions at Sanofi-Synthelabo (now Sanofi) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi, he led the successful worldwide launches of Plavix, Eloxatin and Avapro as Vice President of Worldwide Marketing, Executive Vice President and Chief Operating Officer of U.S. Operations. He served at American Critical Care, a division of American Hospital Supply since November 1980 until September 1987. He served as the Non-Executive Chairman of the Board at AveXis, Inc. from January 2016 to May 15, 2018. Mr. Welch has played leadership roles in the development and commercialization of several blockbuster pharmaceutical brands, including Tysabri, emtricitabine and Esbriet. He has been an Independent Director of Ultragenyx Pharmaceutical Inc. since April 08, 2015. Mr. Welch served as Director of Intercept Pharmaceuticals, Inc. since November 24, 2015 until May 27, 2021. He has been an Independent Director at Seagen Inc. (formerly known as Seattle Genetics, Inc.) since June 14, 2007. Mr. Welch serves as Executive Chairman of Levo Therapeutics, Inc. He serves as a Director at BayBio. He served as a Director of Triangle Pharmaceuticals, Inc. Mr. Welch served as a Director of Hyperion Therapeutics, Inc., from August 2012 to 2015. He served as a Director of the InterMune, Inc. from September 25, 2003 to September 29, 2014. He served as Director of Bay Area Bioscience Association. He served as a Director of Corium International, Inc. from 2007 to December 4, 2014. He serves as Chairman at Nuvation Bio Inc. He has experience in the biotechnology and pharmaceutical industries. Mr. Welch is self-employed as a biotechnology advisor. Mr. Welch holds an MBA from the University of North Carolina and holds a BBA Degree in Marketing from the University of Miami. Mr. Welch holds a BS/BA from the University of Miami.

公司职务